Trials / Conditions / Carcinoma, Bronchogenic

Carcinoma, Bronchogenic

18 registered clinical trials studyying Carcinoma, Bronchogenic — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study NCT06494241	AstraZeneca	—
Active Not Recruiting	Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC NCT06376084	AstraZeneca	—
Recruiting	A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-S NCT06177925	Nanfang Hospital, Southern Medical University	Phase 2
Terminated	(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations NCT05241873	Blueprint Medicines Corporation	Phase 1
Terminated	(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC NCT05153408	Blueprint Medicines Corporation	Phase 1
Terminated	(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC NCT04862780	Blueprint Medicines Corporation	Phase 1
Terminated	A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic NCT04644315	Hoffmann-La Roche	Phase 2
Unknown	External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patien NCT04697446	Blueprint Medicines Corporation	—
Terminated	A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer NCT04222972	Hoffmann-La Roche	Phase 3
Completed	Comparison of Post-operative Pain and Quality of Life Between Subxiphoid and Intercostal VATS for Lung Cancer NCT03331588	Shanghai Pulmonary Hospital, Shanghai, China	Phase 3
Completed	A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC NCT03134872	Jiangsu HengRui Medicine Co., Ltd.	Phase 3
Unknown	A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC NCT03085069	Jiangsu HengRui Medicine Co., Ltd.	Phase 2
Completed	Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Can NCT03037385	Hoffmann-La Roche	Phase 1 / Phase 2
Unknown	Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients NCT02804100	Wenzhou Medical University	—
Unknown	The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial NCT03402048	University of Turin, Italy	Phase 3
Unknown	Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics NCT02441972	Wuxi No. 4 People's Hospital	Phase 1
Completed	A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small C NCT00102505	Pharmacyclics LLC.	Phase 1
Completed	Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer NCT01058785	NovaRx Corporation	Phase 2